Phase II evaluation of fludarabine phosphate in patients with central nervous system tumors. A Southwest Oncology Group trial.
Twenty-three patients with malignant central nervous system tumors were treated with fludarabine phosphate (2-FAMP) on a 5 day bolus schedule. One brief partial response was observed in 20 malignant astrocytoma patients. 2FAMP as given in this protocol is inactive in previously treated patients with recurrent malignant astrocytomas.
Taylor
S A
SA
University of Kansas Medical Center, Kansas City.
Crowley
J
J
Vogel
F S
FS
Townsend
J J
JJ
Eyre
H J
HJ
Jaeckle
K A
KA
Hynes
H E
HE
Guy
J T
JT
D000293:Adolescent; D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012074:Remission Induction / Q000379:methods; D001084:Vidarabine Phosphate / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000964:Antimetabolites, Antineoplastic; D001084:Vidarabine Phosphate; C042382:fludarabine phosphate